Farallon Capital Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,400
| Closed | -$299K | – | 176 |
|
|
2025
Q4 | $299K | Hold |
1,400
| – | – | ﹤0.01% | 110 |
|
|
2025
Q3 | $278K | Hold |
1,400
| – | – | ﹤0.01% | 108 |
|
|
2025
Q2 | $242K | Hold |
1,400
| – | – | ﹤0.01% | 115 |
|
|
2025
Q1 | $218K | Buy |
+1,400
| New | +$200K | ﹤0.01% | 118 |
|
|
2024
Q4 | – | Sell |
-1,400
| Closed | -$209K | – | 156 |
|
|
2024
Q3 | $209K | Buy |
+1,400
| New | +$189K | ﹤0.01% | 141 |
|
|
2024
Q2 | – | Sell |
-109,000
| Closed | -$16.5M | – | 171 |
|
|
2024
Q1 | $16.5M | Buy |
+109,000
| New | +$15.6M | 0.1% | 81 |
|
|
2021
Q3 | – | Sell |
-375,000
| Closed | -$49.3M | – | 303 |
|
|
2021
Q2 | $49.3M | Sell |
375,000
-625,000
| -63% | -$83.3M | 0.24% | 73 |
|
|
2021
Q1 | $129M | Hold |
1,000,000
| – | – | 0.67% | 42 |
|
|
2020
Q4 | $167M | Sell |
1,000,000
-250,000
| -20% | -$41.3M | 1.04% | 39 |
|
|
2020
Q3 | $193M | Buy |
1,250,000
+110,000
| +10% | +$15.8M | 1.37% | 29 |
|
|
2020
Q2 | $169M | Sell |
1,140,000
-236,349
| -17% | -$32.5M | 1.35% | 30 |
|
|
2020
Q1 | $155M | Buy |
1,376,349
+97,349
| +8% | +$12.6M | 1.42% | 28 |
|
|
2019
Q4 | $178M | Sell |
1,279,000
-271,000
| -17% | -$30.1M | 1.37% | 27 |
|
|
2019
Q3 | $149M | Buy |
1,550,000
+10,000
| +0.6% | +$1.12M | 1.22% | 27 |
|
|
2019
Q2 | $177M | Buy |
1,540,000
+40,000
| +3% | +$4.79M | 1.24% | 23 |
|
|
2019
Q1 | $177M | Buy |
1,500,000
+703
| +0% | +$61.6K | 1.46% | 24 |
|
|
2018
Q4 | $93.9M | Buy |
1,499,297
+42,000
| +3% | +$2.64M | 0.82% | 35 |
|
|
2018
Q3 | $103M | Hold |
1,457,297
| – | – | 0.73% | 34 |
|
|
2018
Q2 | $96.9M | Buy |
1,457,297
+170,497
| +13% | +$11.2M | 0.71% | 38 |
|
|
2018
Q1 | $84.2M | Buy |
+1,286,800
| New | +$72.3M | 0.7% | 37 |
|
Other funds holding ASND
RCM
ACA
